ClinicalTrials.gg
CompletedNCT03487211CORTEXUpdated Feb 27, 2020

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

A Phase 2/3 interventional study of Duloxetine and Escitalopram in Fibromyalgia, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-27.

Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Fibromyalgia with a site in Pakistan — 4 open to participants now, 5 under way, none of them phase 3. Fibromyalgia · Pakistan.

Started
2018
the only one that year
Phase 2/3
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
Shaheed Zulfiqar Ali Bhutto Medical University

Among the 10 studies in Fibromyalgia with a site in Pakistan, this one is the only one that started in 2018, is the only one in phase 2/3, and was the 1st registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 10 studies in Fibromyalgia with a site in Pakistan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Fibromyalgia with a site in Pakistan, or all of them as a file.
02

Study summary

Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.

Read the detailed description

180 drug naive patients with newly diagnosed fibromyalga according to the modified ACR 2016 criteria shall be enrolled by consecutive sampling after taking written informed consent. Baseline severity of fibromyalgia shall be assessed via the Revised Fibromyalgia Impact Questionnaire (FIQ-R). They shall be randomized via cluster randomization into two groups. The first group shall receive Duloxetine 30mg, will be increased to 60mg after one week. The second group shall receive Escitalopram 10mg to be increased to 20mg after one week. Patients shall be followed at 0,2,4,8 and 12 weeks. At each visit, any subjective change in symptoms shall be noted and the FIQ-R shall be re administered. At the end of the trial, the overall change in the FIQ-R from baseline shall be assessed and the difference between both groups will be analyzed.

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • Fibromyalgia treatment
  • Duloxetine
  • Escitalopram
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Drug Naive patients
  • Newly diagnosed with FIbromyalgia according to Modified ACR 2016 criteria

Exclusion criteria

Exclusion Criteria:

  • Concomitant depression/bipolar disorder or any other documented psychiatric illness
  • disorders (SLE, RA)
  • Peripheral Neuropathic pain due to any cause
  • Uncontrolled hypertension
  • Impaired renal or hepatic functions (on Lab assay)
  • Chronic infections (e.g.Tuberculosis)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Duloxetine Group

    Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.

    Drug: Duloxetine

  • Experimental
    Escitalopram Group

    Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.

    Drug: Escitalopram

Interventions

  • Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily

    Also known as: DUPREX

  • Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily

    Also known as: EXAPRO

06

What researchers measure

Primary outcomes

  1. Reduction in FIQ-R (Revised Fibromyalgia Impact Questionnaire) from baseline

    Percentage decrease in FIQ-R from baseline

    Time frame: 4,8 and 12 weeks

07

Study locations

1 site
  • Pakistan Institute of Medical Sciences
    Islamabad, Islamabad Capital Territory 44000, Pakistan
08

References and documents

Publications

  • Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009 Jun;36(6):1304-11. doi: 10.3899/jrheum.081090. Epub 2009 Apr 15. PubMed 19369473 ↗
  • Wright CL, Mist SD, Ross RL, Jones KD. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol. 2010 Sep;6(5):745-56. doi: 10.1586/eci.10.64. PubMed 20828282 ↗
  • Smith HS, Bracken D, Smith JM. Pharmacotherapy for fibromyalgia. Front Pharmacol. 2011 Mar 31;2:17. doi: 10.3389/fphar.2011.00017. eCollection 2011. PubMed 21772818 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Feb 2020, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 3, 2018
StartActual
Apr 9, 2018
Primary completionActual
Feb 26, 2020
CompletionActual
Feb 26, 2020
Last update
Feb 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487211
Lead sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Responsible party
DR. MOHAMMAD ALI ARIF (Assistant Professor of Medicine, Shaheed Zulfiqar Ali Bhutto Medical University) — Principal investigator
First posted
Apr 3, 2018
Start date
Apr 9, 2018
Primary completion
Feb 26, 2020
Completion
Feb 26, 2020
Last update
Feb 27, 2020

Study contacts

Mohammad A Arif, MRCP, FRCP
principal investigator · Shaheed Zulfiqar Ali Bhutto Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escitalopram

Start the discussion